Stay on the Cutting Edge of Biotech, MedTech, and Pharma.
100% free, unsubscribe anytime.
Section 232 hits today. The exemptions decide everything. Plus earnings come in strong.
Altimmune's drug cut drinking in a trial. And the big tariffs land tomorrow.
Doubts land days before the adcomm. Plus GSK's $2.5B restructuring and tariffs Friday.
Argenx bought Forte for vitiligo and celiac. Meanwhile Sanofi's $1.4B bet fell apart.
Lilly's triple hormone drug delivered again. Plus tariffs hit Friday and Otsuka landed an ADHD approval.
Its first lung cancer drug, weeks after closing. Plus a transatlantic breast cancer split.
